Although hematologic cancers typically exhibit relatively low P-gp levels, post-treatment genetic instability, and clonal selection in refractory or relapsed patients enhance ABCB1 activation and P-gp overexpression. The gene discussed is PGP; the disease is hematopoietic and lymphoid cell neoplasm.